Hadassah

Hadassah Medical Organization’s Heart Imaging Tracer Advances to First-in-Human Trials with $4M EU Grant

Thursday, Feb 18 2016

MEDIA INQUIRES CONTACT:
Renee Young, National Public Relations
ryoung@hadassah.org
(212) 303- 8140

FOR IMMEDIATE RELEASE

European Union Grant Reaffirms Hadassah's Worldwide Leadership in Heart Research in February during American Heart Month

January 18, 2016 NEW YORK — Jerusalem-based Hadassah Medical Organization's (HMO) innovative radioactive heart imaging tracer project, which enables cardiologists to noninvasively and quantitatively view specific changes of blood flow to the heart, has received a €3.69M ($4M US) grant from the European Union's (EU) Horizon 2020 Program. The grant will enable first-in-human clinical trials (Phase 1) to commence immediately in Jerusalem, announced Ellen Hershkin, National President of Hadassah, The Women's Zionist Organization of America, Inc. (HWZOA).

The innovative radioactive heart imaging tracer, invented and developed by Dr. Eyal Mishani, MD, PhD and HMO's Cyclotron and Radiochemistry Unit team, together with HMO cardiologist Dr. Chaim Dannenberg, MD, PhD, was exclusively licensed in 2013 by Hadasit, HMO's technology transfer company, to the grant applicant Synektik S.A., a leading provider of innovative solutions for Medical Imaging in Europe.

The three year grant for this PET/CT cardiac imaging tracer awarded by EU's Horizon 2020 program is one of only three funded projects from 110 applicants in the health field. Currently, HMO is the only hospital in the world with this imaging agent. The announcement coincides with February Heart Health Month in America and re-affirms HMO's worldwide leadership position in heart research.

This invention heralds a new stage in the diagnosis of cardiovascular disease, the leading cause of death in the world. Currently, millions of diagnostic heart catheterizations are performed each year in the United States; less than 50% reveal heart problems that require further intervention. Thus, the new tracer may decrease unnecessary invasive procedures and costs.

First-in-human trials (Phase 1) will begin at HMO in 2016, the first of its kind in Israel with a PET imaging tracer. HMO has already received the approval of both its Helsinki Ethics Committee and Israel's Ministry of Health to launch the trials.

Hadassah National President Ellen Hershkin states, "One of Hadassah's major focuses is to eradicate heart disease in our lifetime and this is another significant step in HMO's journey to do so."

Prof. Mishani explains: "When this imaging agent is injected into the patient, it accumulates in the heart, enabling the physician to measure blood flow in absolute values and pinpoint the location of problems. With heart disease being the most common cause of death worldwide, the grant is an important recognition by the European Commission for our work in translational medicine, our ability to move from the laboratory to the bedside."

Using quantitative imaging for blood flow to the heart, HMO's new imaging agent will help diagnose coronary artery disease to facilitate more accurate diagnoses and treatment methods. It will also enable doctors to measure the damage caused after a heart attack, and predict the degree of recovery after a heart attack or bypass surgery.

Horizon 2020 is the EU's largest research and innovation program.

For more information on Every Beat Counts, Hadassah's Heart Health Program™, visit http://www.hadassah.org/health-medicine-in-us/heart-health/.

###

Hadassah is the largest Jewish women’s organization in the United States. With 330,000 members, associates and supporters across the country, Hadassah brings Jewish women together to effect change and advocate on criticalissues such as medical care and research, women's empowerment, and the security of Israel. Through the Hadassah Medical Organization's (HMO) two hospitals, the world-renowned trauma center and the leading research facility in Jerusalem, Hadassah supports the delivery of exemplary patient care to over a million people every year. HMO serves without regard to race, religion or nationality and earned a Nobel Peace Prize Nomination in 2005 for building “bridges to peace” through equality in medical treatment. For more information, visit www.hadassah.org.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 30 2016

Hadassah Teams Up with Spinal Cord Institute to Study Outcomes of Traumatic Injuries

The medical interventions and outcomes for Israelis with a spinal cord injury (SCI) will now be captured in the Rick Hansen SCI Registry (RHSCIR), thanks to the November 16th launch of a partnership between the Hadassah Medical Organization and the Rick Hansen Institute (RHI), a Canadian-based not-for-profit organization named after the paralympic athlete who suffered a severe spinal cord injury following a car accident.

READ MORE ›
alt_text

Thursday, Nov 17 2016

A Birthday Party in Hadassah’s PICU: Helping a Four-Year-Old Recover

Yehoshua "Shuki" Pepper was crossing a Jerusalem street with an older sibling when a car ran him over. He was rushed to Hadassah Hospital Ein Kerem's Pediatric Intensive Care Unit in fair condition, but he wasn't speaking and subsequent MRIs of his head injury were worrisome.

READ MORE ›
alt_text

Thursday, Nov 17 2016

Ethiopian Pre-Nursing Students: On the Way to Fulfilling a Dream

“I know that some people are fine with looking at a screen all day, but I know I need the human touch--to work with people. I want to be a nurse, " relates Sarah Talala, one of the 18 students of Ethiopian background who were given the opportunity to take a course which enabled them to advance to pre-academic studies at the Hebrew University and then on to nursing school at the Hadassah-Hebrew University Henrietta Szold School of Nursing.

READ MORE ›
alt_text

Monday, Nov 14 2016

Granalix BioTechnologies Introduces Food Additive to Protect Against Neurodegenerative Disease

Granalix BioTechnologies, whose founder and Chief Executive Officer is Hadassah Medical Organization Experimental Neurologist Prof. Ruth Gabizon, has launched a food supplement containing pomegranate oil that has proven to protect against neurodegenerative diseases in pre-clinical models.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More